Xeris Biopharma Holdings, Inc. (XERS) insider sale under 10b5-1 plan

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. reported that Chief Legal Officer and Corporate Secretary Beth Hecht sold 16,666 shares of common stock on August 3, 2026, in a sale classified as an open-market or private transaction at a weighted average price of $8.0135 per share. The transaction was effected under a Rule 10b5-1 trading plan adopted on August 8, 2025. Following this sale, she directly owned 1,144,462 shares of common stock. The shares were sold in multiple trades at prices between $7.870 and $8.140 per share.

Insider Trade Summary 10b5-1

Net Seller: 16,666 shares

Net Sell 1 txn

Insider Hecht Beth

Role See Remarks

Sold 16,666 shs ($134K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	16,666	$8.0135	$134K

Holdings After Transaction: Common Stock — 1,144,462 shares (Direct)

Footnotes (2)

1. F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.870 to $8.140, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 16,666 shares Weighted average sale price: $8.0135 per share Price range of sales: $7.870 to $8.140 per share +2 more

5 metrics

Shares sold 16,666 shares Common Stock sale on August 3, 2026

Weighted average sale price $8.0135 per share Sale of Common Stock reported for August 3, 2026

Price range of sales $7.870 to $8.140 per share Multiple transactions comprising the reported sale

Shares owned after transaction 1,144,462 shares Direct ownership following the August 3, 2026 sale

Rule 10b5-1 plan adoption date August 8, 2025 Trading plan under which the reported sale was effected

Key Terms

Rule 10b5-1 trading plan, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 05:16 PM Accepted by SEC EDGAR 08/04/2026 - 05:16 PM Learn about SEC filing dates

FAQ

What insider stock sale did Xeris Biopharma (XERS) report for Beth Hecht?

Xeris Biopharma reported that Chief Legal Officer Beth Hecht sold 16,666 shares of common stock. The sale occurred on August 3, 2026, at a weighted average price of $8.0135 per share, in transactions priced between $7.870 and $8.140 per share.

At what prices were Beth Hecht’s XERS shares sold?

The reported weighted average sale price was $8.0135 per share. According to the disclosure, the 16,666 shares of common stock were sold in multiple transactions at prices ranging from $7.870 to $8.140 per share, inclusive.

How many Xeris Biopharma (XERS) shares does Beth Hecht own after this transaction?

After the reported sale, Beth Hecht directly owned 1,144,462 Xeris Biopharma shares. This share count reflects her direct common stock holdings following the August 3, 2026 transaction classified as an open-market or private sale.

Was Beth Hecht’s XERS stock sale made under a Rule 10b5-1 trading plan?

Yes. The sale was effected under a Rule 10b5-1 trading plan. The plan was adopted by Beth Hecht on August 8, 2025, and the August 3, 2026 sale of 16,666 common shares was executed pursuant to that pre-established trading arrangement.

What type of transaction code was used for Beth Hecht’s XERS stock sale?

The transaction used code “S,” indicating a sale in an open market or private transaction. This code applies to the 16,666 common shares sold on August 3, 2026, at a weighted average price of $8.0135 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hecht Beth

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO ILLINOIS 60607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S(1)		16,666	D	$8.0135(2)	1,144,462	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.870 to $8.140, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

Chief Legal Officer and Corporate Secretary

	/s/ Beth Hecht	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)